Navigation Links
Cardiome Discloses Chairman And CEO's Involuntary Share Sale
Date:11/28/2008

NASDAQ: CRME TSX: COM

VANCOUVER, Nov. 28 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today disclosed that its Chairman and Chief Executive Officer, Bob Rieder, was recently subject to involuntary margin sales of 45,000 common shares from his direct holding of Cardiome stock.

Mr. Rieder commented, "I am very disappointed to have been required to involuntarily sell any shares of Cardiome, particularly at such an inopportune time; however the global financial crisis and associated market decline has had a profound impact on all stocks including our own. Since joining Cardiome as CEO in 1998, I have always practiced my belief that the leader of a company should have a direct and material financial stake in the company's success, and I have consistently held a substantial proportion of my personal assets in Cardiome shares. My faith and confidence in Cardiome's success is absolutely undiminished as we drive the company forward to the exciting times that lie ahead."

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ National Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.


'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiome Provides Regulatory Update
2. Cardiome To Release Second Quarter Results And Hold Conference Call
3. Cardiome Announces Preferred Share Financing
4. Cardiome Announces Positive Phase 2b Results For Oral Vernakalant
5. Cardiome To Hold Conference Call
6. Cardiome Reports First Quarter Results
7. Cardiome To Release 2008 First Quarter Results
8. Cardiome To Release 2007 Results
9. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
10. Cardiome And Astellas Announce Regulatory Update
11. Cardiome to Hold Investor Update Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... 23, 2017 , ... Yesterday, U.S. Senate Republicans revealed details ... and replace the Affordable Care Act (ACA). Like the bill narrowly passed by ... a public health insurance program for low-income children, pregnant women, parents of dependent ...
(Date:6/23/2017)... ... 23, 2017 , ... Everybody has their own personal preference when it comes ... and some people don't like it at all. FindaTopDoc took a look at what ... literature can give readers a taste of their deepest, darkest fantasies and has the ...
(Date:6/23/2017)... ... 23, 2017 , ... 21 Middle East and South Asia Leaders Selected as ... government, business and civil society in 11 countries across the Middle East and South ... a transformative exchange of knowledge and ideas with the leading minds in their fields. ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ulster University, Magee Campus in Northern Ireland is ... 3 pm to present to graduate students exciting new and innovative hope research based ... led by The Health Improvement Service of the Western Health & Social Care Trust ...
(Date:6/23/2017)... ... June 23, 2017 , ... Moore Insurance, ... area with access to asset protection and financial planning services, is teaming up ... improving the lives of children with cancer and other chronic diseases. , The ...
Breaking Medicine News(10 mins):
(Date:6/20/2017)... , June 19, 2017  Hill-Rom Holdings, Inc. (NYSE: ... call and webcast on Friday, July 28, 2017, beginning at ... Call Audio Only Dial-in information: To participate in the conference ... dial into the call at least 10 minutes prior to ... is 34090339.  Webcast: ...
(Date:6/14/2017)... , June 14, 2017 The Bio Supply ... City of Fremont and the Biomedical ... bio-pharma industry in California by ... executive networking, and fostering workforce development. The primary focus ... growth of start-ups, as well as small and mid-sized ...
(Date:6/10/2017)... Ala. , June 9, 2017  Shane K. Burchfield, DPM, ... recognized for excellence as a Podiatrist in Alabama ... Podiatry at Family First Foot Care. He brings over 20 years ... medicine, pain management and healthcare, to his role. ... First Foot Care, PC is pleased to welcome you ...
Breaking Medicine Technology: